Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

BACKGROUND: Eribulin mesilate (eribulin), a non-taxane microtubule dynamics inhibitor, has shown trends towards greater overall survival (OS) compared with progression-free survival in late-stage metastatic breast cancer patients in the clinic. This finding suggests that eribulin may have additional...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yoshida, T, Ozawa, Y, Kimura, T, Sato, Y, Kuznetsov, G, Xu, S, Uesugi, M, Agoulnik, S, Taylor, N, Funahashi, Y, Matsui, J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3960630/
https://ncbi.nlm.nih.gov/pubmed/24569463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.80
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados